Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC)

Similar documents
CANCER CACHEXIA. Barry J A Laird Clinician Scientist in Palliative Medicine, University of Edinburgh & European Palliative Care Research Centre

Multimodal cachexia management

Depression in Cancer EAPC Glasgow 2010

THE UNIVERSITY of EDINBURGH

Prognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score

The use of omega-3 fatty acids in the management of cancer cachexia. Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust

Classification of (cancer) cachexia: Any improvements to expect?

Binary Views Oncology

Cancer cachexia: assessment and classification. KCH Fearon University of Edinburgh Scotland

PRAIS Two perspectives. Current cancer pain research 12/4/2015. More complex thinking in cancer pain studies. Usual thinking in cancer pain studies

CANCER PAIN & PALLIATIVE CARE SECTION. Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study

Steps towards an international classification system for cancer pain

Programme overview (subject to change)

Supportive Care makes excellent cancer care possible

Palliative care competencies: is it for all? Khon Kaen International Conference in Palliative Care 2018

Pharmacologic and Nonpharmacologic Interventions for Pain

Palliative Care Management Diploma

Palliative Care The Benefits of Early Intervention

Cancer-induced bone pain

Molecular Mechanisms associated with the Cancer-Cachexia Syndrome

Inaugural Guildford Supportive Care in Cancer Course

Cancer Cachexia. Current and Future Management Options

ESPEN guidelines: Nutritional interventions in advanced cancer care. -An overview and pending research questions

Palliative Care in Patients with Brain Tumors: How to maintain hope and quality of life, even when treatments fail

The Danish Palliative Care Trial (DanPaCT), a randomised trial of early palliative care in cancer. Results of the primary analysis

Syed H Jafri 1,2*, Runhua Shi 1,2 and Glenn Mills 1,2

Clinical Update in Palliative Care

A new era of therapeutics for cancer cachexia. Cachexia is a continuum with 3 stages of clinical relevance

ESPEN Congress Geneva 2014 LLL LIVE COURSE: NUTRITIONAL SUPPORT IN CANCER. Multimodal therapy of cancer cachexia K. Fearon (UK)

CANCER CACHEXIA. Negativity cancer nutrition. Do we think it s s important? Lack of past success alimentation trials counselling therapeutic failures

Nutritional requirements in advanced cancer patients

Integration of palliative care into oncology

ABC of palliative care: Anorexia, cachexia, and nutrition

Symptom management in (specialized) palliative care: who is responsible for what? Rettke, Horst, PhD, RN

Integrating Palliative and Oncology Care in Patients with Advanced Cancer

A Brief Information Sheet On Opioid Effects Improves Quality Of Life In Cancer Patients On Opioids

How to improve the reliability of Single Arm Trials

The Growing Landscape of Palliative Care

Metabolic issues in nutrition: Implications for daily care

What is palliative care? What is palliative care? Dr Claire L Hookey

25/11/2015 OVERVIEW DEFINITION OF PALLIATIVE CARE FURTHERMORE.. PALLIATIVE PERFORMANCE SCALE (PPS) CACHEXIA OF ADVANCED DISEASE

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer

Health-related quality of life a prospective cohort study in phase I oncology trial participants 1

The correlation between a chronic inflammatory marker Tartrate-Resistant Acid Phosphatase 5a with cancer cachexia

Outcome following surgery for colorectal cancer

Ingvar Bosaeus, MD, Sahlgrenska University Hospital, Goteborg, Sweden

Programme Day : Chairman s introduction : Supportive care an overview Declan Walsh

Integration of Palliative and Oncology Care in patients with lung and other

Quality of Life. The assessment, analysis and reporting of patient-reported outcomes. Third Edition

Running Head: EFFECTS OF RESVERATROL ON CANCER CACHEXIA 1. Effects of resveratrol on cancer cachexia in a mouse model.

ESPEN Congress Leipzig 2013

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

Subject Index. rationale for supplementation in cancer patients 260, 273 surgical cancer patient supplementation

Romayne Gallagher MD, CCFP Divisions of Residential and Palliative Care Providence Health Care Vancouver, BC

Symptom Assessment in Palliative Care

Nutrition and oncology: medical aspects. Case history. What is cancer? Head, Palliative Care RPAH/Sydney Cancer Centre May 2008

To prevent and relieve suffering, and promote quality of life at every stage of life

Nutrition support for sarcopenia in cancer patients

The century of the system

Prognostic value of changes in quality of life scores in prostate cancer

Palliative Care in the Continuum of Oncologic Management

How Many Times? Result: an Unsatisfactory Outcome That Can Be Avoided

Curriculum vitae and list of publications

EfS Evaluation Data. Prepared by Prof Dawn Skelton, Glasgow Caledonian University from data sent by Trish Cowie. Feb 2013.

Objectives. WHO definition of palliative care. 50% of patients with cancer will die of their disease (NCIC, 2005)

Line Murtnes Hagestande

SERUM CYTOKINES ARE ELEVATED IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS) BUT LARGELY UNRELATED TO SYMPTOM CHARACTERISTICS

Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer

PALLIATIVE CARE IN END-STAGE LIVER DISEASE

nutrition and cancer Weight loss and Quality of Life (QoL) Nutrition and QoL wound healing Surgery & RT hospital stay rehospitalisations Malabsorption

Single Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer

Optimal preparation for cancer treatment. Dr Jann Arends Tumor Biology Center Freiburg Germany

The QLQ-C30 cut-off project - Symptom screening with the EORTC quality of life scales

Palliative care in long-term conditions Scottish Palliative Care Pharmacists Association

patient decision aid advanced lung cancer

Connections Between Autoimmune Disease & Cancer

Introduction To Pain Management In Palliative Care

FILE // WHAT ARE TUMOR SUPPRESSOR GENES EBOOK

Appendix F- Edmonton Symptom Assessment System (ESAS), Canadian Problem Checklist, and Distress Thermometer for Cancer Patients

Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?

Multidimensional Measurement of Fatigue in Advanced Cancer Patients in Palliative Care: An Application of the Multidimensional Fatigue Inventory

Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer

Carcinosarcoma Trial rial in s a in rare malign rare mali ancy

How Long Do I Have? The Art and Science of Prognostication

Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer

Cancer Pain Assessment and Classification

Combination therapy in cachexia

Diet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford

Palliative Medicine Overview. Francine Arneson, MD Palliative Medicine

Early Integration of Palliative Care

Immunological biomarkers predictive of clinical response to chemotherapy and maintenance HAART in HIV + patients with Kaposi sarcoma

Assessing Toxicity Risk in Senior Chemotherapy Patients (AT RISC) a pilot prospective audit

European Journal of Oncology Nursing

How I treat High-risk follicular lymphoma

THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION

Depression - a major contributor to poor quality of life in patients with advanced cancer

ESPEN Congress Copenhagen 2016

Transcription:

1 Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC) 2 Acknowledgements Prof Marie Fallon (group lead EPAS) University of Edinburgh Prof Ken Fearon NTNU Prof P Klepstad, Prof S Kaasa, Prof P Fayers University of Glasgow Prof D McMillan 1

3 Symptom Prevalence in Advanced Cancer Teunissen et al, JPSM 2007 4 Are cancer pain and depression interdependent? Laird BJA, Boyd AC, Colvin LA, Fallon MT. Psycho-oncology 2008. DOI: 10.1002/pon.1431 Pain intensity, duration and certain descriptors (MPQ) associated with depression. Pain and depression both highly prevalent Certain pain features correlated with depression 2

5 6 Symptom Cluster In advanced cancer, a median of 11 symptoms (range 1 27) are present commonly (Walsh et al., 2000). Symptoms can simply co exist Symptoms can co exist and be related Symptoms can co exist and share a common pathophysiology Symptom cluster: three or more concurrent symptoms that are related to each other is the most appropriate definition (Dodd et al., 2001b). 3

7 Pain, depression and fatigue as a symptom cluster in advanced cancer. Laird et al. Journal of Pain and Symptom Management Vol 42, No1, 2011 n=654 Patients with moderate under nutrition EORTC QLQ C30 Cut offs based on thresholds Multivariate and regression analyses run 8 Trial A (n=473) Trial B (n=181) Depression* Fatigue** Pain*** Observed Expected Observed Expected Prevalence Prevalence@ Prevalance Prevalence@ No No No 130 (27.5%) 71.2 (15.1%) 58 (32.0%) 39.0 (21.6%) No No Yes 25 (5.3%) 48.7 (10.3%) 23 (12.7%) 29.6 (16.3%) No Yes No 40 (8.5%) 58.7 (12.4%) 11 (6.1%) 22.4 (12.4%) No Yes Yes 24 (5.1%) 40.2 (8.5%) 16 (8.8%) 17.0 (9.4%) Yes No No 62 (13.1%) 82.6 (17.5%) 23 (12.7%) 26.4 (14.6%) Yes No Yes 42 (8.9%) 56.5 (11.9%) 11 (6.1%) 20.0 (11.0%) Yes Yes No 49 (10.4%) 68.3 (14.4%) 11 (6.1%) 15.1 (8.4%) Yes Yes Yes 101 (21.4%) 46.6 (9.9%) 28 (15.5%) 11.5 (6.3%) 4

9 Pain, Depression, Fatigue Symptom Cluster Pain, depression and fatigue exists as a specific symptom cluster in advanced cancer patients. Between Two and four times the number of patients with all three symptoms than would be expected. (p<0.001) Each symptom can occur in isolation and every possible pair of symptoms can occur without the third being present. This further supports the existence of pain, depression and fatigue as a specific symptom cluster. First study to demonstrate this cluster 10 Cytokine Induced Sickness Behaviour Administration of inflammatory agents and pro inflammatory cytokines results in cytokine induced sickness behaviour (Konsman et al., 2002, Dantzer, 2004). Cytokine induced sickness behaviour produces pain and behavioural changes which are comparable with pain, depression and fatigue in humans (Yirmiya, 1996, Watkins and Maier, 2000). In humans the response to infection, results in increased production of pro inflammatory cytokines (IL 1, IL 6 and TNFalpha). These pro inflammatory cytokines correlate with clinical symptoms which mirror animal models of sickness behaviour (Vollmer Conna et al., 2004). Cytokine induced sickness behaviour resulting in pain, depression and fatigue, has been shown to exist not demonstrated in cancer... 5

11 Inflammation & Cancer Inflammation predisposes to certain tumour types Inflammation implicated in oncogenic mutations & experimental animal models of tumour development 1 Inflammation can be a result of cancer. Targeting inflammation can reduce cancer risk and cancer spread. 7 th hallmark of cancer 1.Mantovani Nature 2008;454 12 6

13 Measuring inflammation CRP Reliable biomarker of SI in cancer Half life of CRP is 19hrs CRP is produced under the control of interleukin 6 (IL 6). IL 6 pro inflammatory cytokine and is a critical mediator of inflammation. IL 6 concentrations are highly correlated with CRP CRP serves as a biomarker for systemic inflammation ~ IL 6 14 7

15 Aim: assess relationship between pain and systemic inflammation cohort of cancer patients; Secondary analysis of BH 80 and Scotia trials (JCO, Gut) n=449, groups well matched CRP used (surrogate IL 6) 16 Relationship between pain and CRP Trial 1 N=275 CRP Trial 2 N=174 CRP Pain Pain Pain Pearson Correlation Significance (2-tailed) Number of patients 0.126 0.163 0.036 0.032 275 174 8

17 Pain and systemic inflammation Pain associated with IL 6 Supported in basic science work (IL 6 knockout mice) (Ramer 1998) IL 6 admin results in allodynia and hyperalgesia (DeLeo 1996) Inflammatory pain IL 6 increased Glial activation and IL 6 (Wieseler Frank 2004) 18 Cancer Symptoms Pain Depression Fatigue Opioids Symptom Clusters Systemic inflammation Prognosis 9

19 Modulating the inflammatory response to treat symptoms? 20 10

21 Symptoms linked Symptoms related to inflammation Inflammation related to prognosis Are symptoms related to prognosis? 22 World Health Organization definition of palliative care: an approach that improves the quality of life of patients and their families facing the problem associated with life threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychological and spiritual 11

23 Systemic Inflammatory Response ANABOLIC BLOCKADE Cachexia Anorexia Physical Inactivity Interventions should be multimodal tackling all of these issues simultaneously 24 premenac Study A multicentre, open, randomized phase II study comparing a multimodal intervention (oral nutritional supplements, celecoxib and physical exercise) for cachexia versus standard cancer care. (EudraCT number: 2010 022897 14) Modulating the inflammatory response on a background of optimal symptom control. 12

25 Thank you. barry.laird@ed.ac.uk 13